Translational Research
Volume 155, Issue 3 , Pages 142-147 , March 2010

Resistin gene promoter region polymorphism and the risk of hypertrophic cardiomyopathy in patients

  • Sabir Hussain

      Affiliations

    • Department of Biochemistry, Quaid-i-Azam University, Islamabad, Pakistan
    • ,
  • Muhammad Asghar

      Affiliations

    • Siddique Sadiq Memorial Trust Cardiac Institute, Gujranwala, Pakistan
    • ,
  • Qamar Javed

      Affiliations

    • Department of Biochemistry, Quaid-i-Azam University, Islamabad, Pakistan
    • Corresponding Author InformationReprint requests: Dr. Qamar Javed, Department of Biochemistry, Quaid-i-Azam University, Islamabad 45320, Pakistan

Received 9 June 2009 ,Revised 8 October 2009 ,Accepted 12 October 2009.

References 

  1. Spirito P, Seidman CE, McKenna WJ, Maron BJ. The management of hypertrophic cardiomyopathy. N Engl J Med. 1997;336:775–785
  2. Wolf CM, Moskqwitz IP, Arno S, et al. Somatic events modify hypertrophic cardiomyopathy pathology and link hypertrophy to arrhythmia. Proc Natl Acad Sci U S A. 2005;102:18123–18128
  3. Kofflard MJ, Ten Cate FJ, Van der Lee C, van Domburg RT. Hypertrophic cardiomyopathy in a large community-based population: clinical outcome and identification of risk factors for sudden cardiac death and clinical deterioration. J Am Coll Cardiol. 2003;41:987–993
  4. Hoffmann B, Schmidt-Traub H, Perrot A, Osterziel KJ, Gessner R. First mutation in cardiac troponin C, L29Q, in a patient with hypertrophic cardiomyopathy. Hum Mutat. 2001;17:524
  5. Olson TM, Karst ML, Whitby FG, Driscoll DJ. Myosin light chain mutation causes autosomal recessive cardiomyopathy with mid-cavitary hypertrophy and restrictive physiology. Circulation. 2002;105:2337–2340
  6. Niimura H, Bachinski LL, Sangwatanaroj S, et al. Mutations in the gene for cardiac myosin-binding protein C and late-onset familial hypertrophic cardiomyopathy. N Engl J Med. 1998;338:1248–1257
  7. Hayashi T, Arimura T, Itoh-Satoh M, et al. Tcap gene mutations in hypertrophic cardiomyopathy and dilated cardiomyopathy. J Am Coll Cardiol. 2004;44:2192–2201
  8. Steppan CM, Bailey ST, Bhat S, et al. The hormone resistin links obesity to diabetes. Nature. 2001;409:307–312
  9. Patel L, Buckels AC, Kinghorn IJ, et al. Resistin is expressed in human macrophages and directly by PPAR gamma activators. Biochem Biophys Commun. 2003;300:472–476
  10. Qiao XZ, Yang YM, Xu ZR, Yang LA. Relationship between resistin level in serum and acute coronary syndrome or stable angina pectoris. J Zhejiang Univ Sci B. 2007;8:875–880
  11. Cho YM, Youn BS, Chung SS, et al. Common genetic polymorphisms in the promoter of resistin gene are major determinants of plasma resistin concentration in humans. Diabetologia. 2004;47:559–565
  12. Azuma K, Oguchi S, Matsubara Y, et al. Novel resistin promoter polymorphisms: association with serum resistin level in Japanese obese individuals. Horm Metab Res. 2004;36:564–570
  13. Osawa H, Yamada K, Onuma H, et al. The G/G genotype of a resistin single-nucleotide polymorphism at –420 increases type 2 diabetes mellitus susceptibility by inducing promoter activity through specific binding of Sp1/3. Am J Hum Genet. 2004;75:678–686
  14. Tang NP, Wang LS, Yang L, et al. A polymorphism in the resistin gene promoter and the risk of coronary artery disease in a Chinese population. Clin Endocrinol. 2008;68:82–87
  15. Kunnari A, Ukkola O, Kesäniemi YA. Resistin polymorphisms are associated with cerebrovascular disease in Finnish Type 2 diabetic patients. Diabet Med. 2005;22:583–589
  16. Kim M, Oh JK, Sakata S, et al. Role of resistin in cardiac contractility and hypertrophy. J Mol Cell Cardiol. 2008;45:270–280
  17. McKenna WJ, Spirito P, Desnos M, Dubourg O, Komajda M. Experience from clinical genetics in hypertrophic cardiomyopathy: proposal for new diagnostic criteria in adult members of affected families. Heart. 1997;77:130–132
  18. Hall TA. BioEdit: a user friendly biological sequence alignment editor and analysis program for windows 95/98/NT. Nucli Acid Symp. 1999;4195–4198
  19. Tsukahara T, Nakashima E, Watarai A, et al. Polymorphism in resistin promoter region at–420 determines the serum resistin levels and may be a risk marker of stroke in Japanese type 2 diabetic patients. Diabetes Res Clin Pract. 2009;84:179–186
  20. Chu S, Ding W, Li K, Pang Y, Tang C. Plasma resistin associated with myocardium injury in patients with acute coronary syndrome. Circ J. 2008;72:1249–1253
  21. Reilly MP, Lehrke M, Wolfe ML, Rohatgi A, Lazar MA, Rader DJ. Resistin is an inflammatory marker of atherosclerosis in humans. Circulation. 2005;111:932–939
  22. Weikert C, Westphal S, Berger K, et al. Plasma resistin levels and risk of myocardial infarction and ischemic stroke. J Clin Endocrinol Metab. 2008;93:2647–2653
  23. Takeishi Y, Niizeki T, Arimoto T, et al. Serum resistin is associated with high risk in patients with congestive heart failure—a novel link between metabolic signals and heart failure. Circ J. 2007;71:460–464
  24. Osawa H, Onuma H, Ochi M, et al. Resistin SNP-420 determines its monocyte mRNA and serum levels inducing type 2 diabetes. Biochem Biophys Res Commun. 2005;335:596–602

 Supported by a research grant from the Higher Education Commission, Pakistan, for a Ph.D. study.

PII: S1931-5244(09)00302-8

doi: 10.1016/j.trsl.2009.10.002

Translational Research
Volume 155, Issue 3 , Pages 142-147 , March 2010

Article Tools